Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.40 |
| ▸ | GRM6 | O15303 | 1/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1508976 | 1.00 | MAPT (0.43) | MAPTSIGMAR1GRM6TMEM97OPRM1 | |
| SCHEMBL1508882 | 1.00 | MAPT (0.43) | MAPTSIGMAR1GRM6TMEM97OPRM1 | |
| SCHEMBL24802004 | 0.83 | MAPT (0.44) | MAPTSIGMAR1TMEM97ACHELMNA | |
| SCHEMBL24801996 | 0.83 | MAPT (0.44) | MAPTSIGMAR1TMEM97ACHELMNA | |
| SCHEMBL22661900 | 0.82 | GRM6 (0.37) | MAPTSIGMAR1GRM6OPRM1OPRL1 | |
| SCHEMBL7918136 | 0.82 | GRM6 (0.37) | MAPTSIGMAR1GRM6OPRM1OPRL1 | |
| SCHEMBL22661873 | 0.82 | GRM6 (0.37) | MAPTSIGMAR1GRM6OPRM1OPRL1 | |
| SCHEMBL2491207 | 0.79 | GRM6 (0.40) | SIGMAR1GRM6 | |
| SCHEMBL25590797 | 0.78 | SIGMAR1 (0.49) | MAPTSIGMAR1TMEM97OPRM1 | |
| SCHEMBL2489070 | 0.76 | CYP2C19 (0.35) | MAPTSIGMAR1GRM6OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370800-B2 | Process for the preparation of cyclopropyldiketopiperazines and of a key intermediate of DS-5272 | F.I.S.—Fabbrica Italiana Sintetici S.p.A. (IT) | 2022-06-28 | — | — | US | disclosed |
| US-20200377521-A1 | PROCESS FOR THE PREPARATION OF CYCLOPROPYLDIKETOPIPERAZINES AND OF A KEY INTERMEDIATE OF DS-5272 | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2020-12-03 | — | — | US | disclosed |
| US-10836778-B2 | Process for the preparation of cyclopropyldiketopiperazines and of a key intermediate of DS-5272 | F.I.S.—Fabbrica Italiana Sintetici S.p.A. (IT) | 2020-11-17 | — | — | US | disclosed |
| EP-2380892-A1 | IMIDAZOTHIAZOLE DERIVATIVE HAVING PROLINE RING STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010082612-A1 | IMIDAZOTHIAZOLE DERIVATIVE HAVING PROLINE RING STRUCTURE | 第一三共株式会社 (JP) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10836778-B2 | Process for the preparation of cyclopropyldiketopiperazines and of a key intermediate of DS-5272 | DHPS, DUS2, RPS2 | MAPT 1405/4885SIGMAR1 3520/4885GRM6 3690/4885 |
| US-11370800-B2 | Process for the preparation of cyclopropyldiketopiperazines and of a key intermediate of DS-5272 | DHPS, DUS2, RPS2 | MAPT 1405/4885SIGMAR1 3520/4885GRM6 3690/4885 |
| US-20200377521-A1 | PROCESS FOR THE PREPARATION OF CYCLOPROPYLDIKETOPIPERAZINES AND OF A KEY INTERMEDIATE OF DS-5272 | DHPS, DUS2, RPS2 | MAPT 1405/4885SIGMAR1 3520/4885GRM6 3690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.